The resident, identified as R#1 in the December 23 inspection report, required Ingrezza 80 mg administered through her feeding tube to control the involuntary movement disorder. Her doctor warned that without the medication, "her symptoms from Tardive Dyskinesia would return."
The medication delay began when the doctor wrote orders for Ingrezza on a specific date with an immediate start date. The Director of Nursing placed a verbal order to the pharmacy the same day, but complications quickly emerged.
The pharmacy technician requested a written, signed order from the DON. She provided it, but didn't discover until the following Monday morning that the pharmacy lacked the prescription in stock.
"The DON stated she placed a follow up call to the pharmacy and she was told the prescription had been ordered from the manufacturer and the expectation was that it would arrive," according to the inspection report.
The facility's hands were further tied by insurance coverage gaps. The DON told inspectors she couldn't pre-order the medication because the resident didn't have prescription coverage until a later date.
This timing problem created a dangerous window where the resident remained without her prescribed treatment for tardive dyskinesia, a serious neurological condition characterized by repetitive, involuntary movements.
The prescribing doctor emphasized the medication's critical importance during his interview with inspectors. He confirmed that Ingrezza was "the only one of its kind that can be administered via a feeding tube" for the resident's condition, meaning no alternative existed.
Recognizing the urgency, the doctor worked directly with the manufacturer's representative to secure emergency samples. "The Doctor stated he was working with the Manufacture Representative to try and get samples delivered to the facility as soon as possible," inspectors noted.
However, the doctor also made a contradictory statement about the medication's necessity. While warning that the resident's symptoms would return without Ingrezza, he also told inspectors: "We have studied this medication, and the patient would not have any escalation of symptoms if she did not get this medication."
The facility's own policies required medications to be administered within a strict timeframe. According to the nursing policies and procedures for medication management, "medications are administered no more than one hour before to one hour after the medication pass time."
Federal regulations mandate that nursing homes "provide or obtain routine medications and biologicals to meet the needs of each resident." The facility's pharmacy services policies specifically address acquisition of routine medication orders for new admissions, readmissions, and new orders.
These policies require that "all medications and biological orders are written, dated and signed by the Physician/Prescriber lawfully authorized to give such an order" and that facilities "fax hard copy physician/prescriber orders to the pharmacy, when applicable."
The DON appeared to follow proper ordering procedures by obtaining the written, signed order and submitting it to the pharmacy. But the breakdown occurred in the coordination between prescription coverage timing and pharmacy inventory management.
Tardive dyskinesia typically develops as a side effect of long-term use of certain psychiatric medications. The condition causes involuntary, repetitive movements that can affect the face, tongue, lips, and other body parts. Without proper medication management, symptoms can worsen or become permanent.
Ingrezza, approved by the FDA in 2017, represents a significant advancement in treating tardive dyskinesia. The medication works by reducing the abnormal dopamine signaling that causes the involuntary movements. For residents who require feeding tube administration, options become even more limited.
The resident's dependence on tube feeding added another layer of complexity to her care. Not all tardive dyskinesia medications can be safely administered through feeding tubes, making Ingrezza particularly crucial for her treatment plan.
The insurance coverage gap that prevented pre-ordering highlights a common challenge in nursing home medication management. Residents transitioning between coverage plans or waiting for new coverage to begin can experience dangerous delays in receiving prescribed medications.
Federal inspectors classified this violation under tag F755, relating to unnecessary medications and medication errors. They determined the incident caused "minimal harm or potential for actual harm" and affected "few" residents.
The inspection was conducted in response to a complaint, suggesting that someone - possibly a family member, resident, or staff member - reported concerns about medication delays at the facility.
San Gabriel Rehabilitation and Care Center's failure to ensure timely medication delivery violated federal requirements that nursing homes provide necessary medications to meet residents' needs. The facility must demonstrate systems to prevent similar delays, particularly for residents with complex medical conditions requiring specialized medications.
The resident with tardive dyskinesia remained vulnerable to symptom recurrence while waiting for her prescribed medication, despite her doctor's clear warnings about the consequences of treatment interruption.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for San Gabriel Rehabilitation and Care Center from 2025-12-23 including all violations, facility responses, and corrective action plans.
Additional Resources
- View all inspection reports for San Gabriel Rehabilitation and Care Center
- Browse all TX nursing home inspections